Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

(2015) Enchi Liu et al.   NEUROLOGY

Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

(2014) Francesco Panza et al.   Expert Review of Neurotherapeutics

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

(2013) Kaj Blennow et al.   NEUROPSYCHOPHARMACOLOGY

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY